Karyopharm Therapeutics Inc.

DB:25K0 Stock Report

Market Cap: €45.9m

Karyopharm Therapeutics Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

DB:25K0 Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
06 May 25Sell€1,481Richard PaulsonIndividual236€6.27
23 Apr 25Sell€2,274Reshma RangwalaIndividual419€5.43
04 Apr 25Sell€834Richard PaulsonIndividual245€3.40
04 Mar 25Sell€3,411Kristin AbateIndividual571€5.97
04 Mar 25Sell€21,192Stuart PoultonIndividual3,548€5.97
04 Mar 25Sell€16,683Michael ManoIndividual2,793€5.97
04 Mar 25Sell€20,577Sohanya ChengIndividual3,445€5.97
04 Mar 25Sell€69,848Richard PaulsonIndividual11,694€5.97
04 Mar 25Sell€21,425Reshma RangwalaIndividual3,587€5.97
18 Feb 25Sell€3,562Stuart PoultonIndividual394.27€9.03
04 Feb 25Sell€2,568Richard PaulsonIndividual273.27€9.40
06 Jan 25Sell€3,056Richard PaulsonIndividual270.33€11.30
04 Dec 24Sell€2,784Richard PaulsonIndividual241.33€11.54
05 Nov 24Sell€3,065Richard PaulsonIndividual245€12.51
04 Oct 24Sell€2,893Richard PaulsonIndividual240.47€12.03
04 Sep 24Sell€3,489Sohanya ChengIndividual357.07€9.77
04 Sep 24Sell€4,592Michael MasonIndividual470€9.77
04 Sep 24Sell€2,389Richard PaulsonIndividual244.47€9.77
04 Sep 24Sell€2,587Michael ManoIndividual264.73€9.77
06 Aug 24Sell€3,069Richard PaulsonIndividual240.53€12.76
30 Jul 24Sell€2,829Stuart PoultonIndividual192.2€14.72
05 Jul 24Sell€2,842Richard PaulsonIndividual241.07€11.79
07 Jun 24Sell€726,307Delphi Ventures, LLCCompany54,536.29€13.64
04 Jun 24Sell€809,356Delphi Ventures, LLCCompany60,411.9€13.79
04 Jun 24Sell€593Michael MasonIndividual43.47€13.65
04 Jun 24Sell€3,268Richard PaulsonIndividual239.47€13.65

Insider Trading Volume

Insider Buying: 25K0 insiders have only sold shares in the past 3 months.

Ownership Breakdown

What is the ownership structure of 25K0?
Owner TypeNumber of SharesOwnership Percentage
Individual Insiders103,1561.2%
Hedge Funds649,6597.58%
Institutions3,813,96744.5%
General Public4,003,39546.7%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Top 25 shareholders own 52.96% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
7.58%
Highbridge Capital Management, LLC
649,659€3.5m0%0.54%
5.95%
The Vanguard Group, Inc.
510,294€2.7m0%no data
5.35%
J. Wood Capital Advisors LLC, Asset Management Arm
458,135€2.5m0%no data
4.92%
Adage Capital Management, L.P.
421,323€2.3m46.3%no data
3.82%
Palo Alto Investors LP
327,133€1.8m-3.83%0.38%
2.83%
BlackRock, Inc.
242,742€1.3m-3.39%no data
2.73%
Morgan Stanley, Investment Banking and Brokerage Investments
234,164€1.3m2,770%no data
2.41%
Citadel Advisors LLC
206,911€1.1m0%no data
1.87%
Marshall Wace LLP
160,094€856.9k15.3%no data
1.82%
Catalio Capital Management, LP
155,625€833.0k0%0.23%
1.62%
Eversept Partners, L.P.
139,250€745.3k-62.4%0.1%
1.57%
Avidity Partners Management, L.P.
134,566€720.3k-57.4%0.1%
1.17%
C WorldWide Asset Management Fondsmaeglerselskab A/S
100,000€535.3k0%0.01%
1.15%
UBS O'Connor LLC
98,915€529.4k24%0.05%
1.08%
Geode Capital Management, LLC
92,820€496.8k2.72%no data
1.02%
BNP Paribas Arbitrage Sa, Asset Management Arm
87,592€468.8k-33.7%no data
0.94%
Renaissance Technologies LLC
80,172€429.1k-3.13%no data
0.93%
Kennedy Capital Management LLC
79,686€426.5k-0.72%0.01%
0.9%
Millennium Management LLC
76,960€411.9k-8.03%no data
0.77%
Goldman Sachs Group, Investment Banking and Securities Investments
66,088€353.7k-25.8%no data
0.58%
Jane Street Group, LLC, Asset Management Arm
49,887€267.0k265%no data
0.58%
Altium Capital Management LP
49,333€264.1k0%0.8%
0.52%
Susquehanna International Group, LLP, Asset Management Arm
44,276€237.0k120%no data
0.46%
Silverarc Capital Management, LLC
39,732€212.7k6.72%0.07%
0.39%
Macquarie Investment Management Business Trust
33,333€178.4k0%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/12 19:20
End of Day Share Price 2025/05/09 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Karyopharm Therapeutics Inc. is covered by 19 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Colleen KusyBaird
Peter LawsonBarclays
Ying HuangBofA Global Research